Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison

Nivolumab and cabozantinib, two new treatment options for previously-treated advanced/metastatic renal cell carcinoma (aRCC), have recently been approved.
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Source Type: research